Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

ed "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," in the online version of the journal Clinical Cancer Research that showed that 100% of 14 evaluable patients were stable disease or better (7 partial responses, and 7 stable disease); - A poster presentation at the American Association for Cancer Research's 101st Annual Meeting in Washington, DC entitled "Reovirus replication in ovarian and peritoneal tumors after intravenous administration," covering correlative results from a Phase 1/2 study with reovirus in patients with ovarian, primary peritoneal and fallopian tube carcinoma, sponsored by the National Cancer Institute under its Clinical Trials Agreement with Oncolytics;

Clinical Program

        -  Opening of enrollment in the Phase 3 trial examining REOLYSIN in
           combination with paclitaxel and carboplatin in patients with
           platinum-refractory head and neck cancers;
        -  Receipt of a No Objection Letter from Health Canada to conduct its
           Phase 3 trial examining REOLYSIN in combination with paclitaxel
           and carboplatin in patients with platinum-refractory head and neck
           cancers;
        -  Receipt of approval from the Belgian Federal Agency for Medicines
           and Health Products (FAMHP) to conduct its Phase 3 trial examining
           REOLYSIN in combination with paclitaxel and carboplatin in
           patients with platinum-refractory head and neck cancers;
        -  Start of enrollment in a U.S. Phase 2 clinical trial using
           intravenous administration of REOLYSIN in combination with
           gemcitabine (Gemzar(R)) in patients with advanced pancreatic
           cancer at the Cancer Therapy & Research C
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/31/2015)... 31, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has filed its Annual ... Exchange Commission. The filed Form 20-F includes audited financial ... The Form 20-F can be accessed by visiting the ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... Dec. 20 ISTO Technologies, Inc., a privately,held orthobiologic ... Finance Forum in San Francisco, CA from January 7-8, ... will present on,Tuesday, January 8th at 11:00 a.m. Pacific ... St. Information about the OneMedPlace Finance Forum may,be found ...
... First IND Candidate Advances for Potential Co-Development Opportunity in ... Oncology ... (Nasdaq: EXEL ) today announced that it has submitted a,comprehensive ... ). Bristol- Myers Squibb Company now has until the end of ...
... ... - Lead compound AEG40826 works synergistically with HGS TRAIL receptor ... -, - IAP inhibitors also show promise alone and in combination ... agents across broad range of cancers -, ROCKVILLE, Md. and MONTREAL, Quebec, ...
Cached Biology Technology:Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 2Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 3Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 2Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 3Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 5Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 6
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... A new study shows that parents are more likely to ... like a traffic light, than the standard charts currently in ... doctor to parent could lead to parents earlier awareness of ... important lifestyle changes," says Eliana Perrin, M.D., M.P.H., senior and ...
... Medicine (NLM) today launched the Newborn Screening Coding ... step toward efficient electronic exchange of standard newborn ... in collaboration with the Office of the National ... and Services Administration, and the Centers for Disease ...
... Physicists at the University of Toronto have discovered that changes ... reduce the amount of ultraviolet (UV) radiation in northern high ... regions of the Earth, such as the tropics and Antarctica, ... "Climate change is an established fact, but scientists are only ...
Cached Biology News:UNC study: Color-coded chart improves parents' understanding of body mass index 2New Web site promotes interoperable newborn screening data 2University of Toronto study shows disparity of effect of climate change on UV radiation 2
CBF-B (G-2)...
... B Receptor Like Protein 2 ... (ETBR-LP-2) has been reported in human ... human brain and colon libraries. ... the amino acid sequence is considered ...
HSV-2 gD (0191)...
... The epitope recognized by A300-183A ... isoform 5 of human quaking ... (GeneID 9444). The epitope ... 1, 2, 3, 4, 6, ...
Biology Products: